US FDA approves Pfizer's pain-relief nasal spray for migraine
FirstpostThe drug, whose pricing will be revealed at a launch in July, is ’expected to be comparable in price to other FDA approved migraine medicines’ which belong to the same class of drugs The US Food and Drug Administration on Friday approved Pfizer Inc’s nasal spray for migraine, giving patients access to a potentially fast-acting pain-relief option for headaches. The drug, whose pricing will be revealed at launch in July, is “expected to be comparable in price to other FDA approved migraine medicines” which belong to the same class of drugs, the company told Reuters. Pfizer added Zavzpret and other migraine treatments, including Nurtec ODT, to it drugs portfolio through its $11.6 billion buyout of Biohaven Pharmaceutical last year. Zavzpret belongs to a class of drugs called calcitonin gene-related peptide inhibitors and will compete with other therapies from AbbVie Inc, Eli Lilly and Co, Amgen Inc and Teva Pharmaceutical.
History of this topic
Zydus gets USFDA nod for generic version of anti-epilepsy drug
The HinduDiscover Related